Benchmark of BINN, GraphPath, and PATH on 2622 TCGA patients shows PATH best for targeted therapy, BINN for survival, none useful for radiation, with GraphPath at 0.92 AUROC on prostate targeted therapy.
Nature598, 7880 (2021), 348–352
1 Pith paper cite this work. Polarity classification is still indexing.
1
Pith paper citing it
fields
cs.LG 1years
2026 1verdicts
UNVERDICTED 1representative citing papers
citing papers explorer
-
TRAPS: Therapeutic Response Analysis via Pathway-informed Stratification
Benchmark of BINN, GraphPath, and PATH on 2622 TCGA patients shows PATH best for targeted therapy, BINN for survival, none useful for radiation, with GraphPath at 0.92 AUROC on prostate targeted therapy.